{"id":"https://openalex.org/W2009929835","doi":"https://doi.org/10.1097/00000421-199010000-00008","title":"Phase II Study of Interferon \u03b1-2a and Dacarbazine in Advanced Melanoma","display_name":"Phase II Study of Interferon \u03b1-2a and Dacarbazine in Advanced Melanoma","alternate_titles":[],"publication_year":1990,"publication_date":"1990-10-01","ids":{"openalex":"https://openalex.org/W2009929835","doi":"https://doi.org/10.1097/00000421-199010000-00008","mag":"2009929835","pmid":"https://pubmed.ncbi.nlm.nih.gov/2220660"},"language":"en","primary_location":{"id":"doi:10.1097/00000421-199010000-00008","doi":"https://doi.org/10.1097/00000421-199010000-00008","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00000421-199010000-00008","pdf_url":null,"source":{"id":"https://openalex.org/S130927242","display_name":"American Journal of Clinical Oncology","issn_l":"0277-3732","issn":["0277-3732","1537-453X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2009929835"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5070704228","display_name":"Emilio Bajetta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"E. Bajetta","raw_affiliation_strings":["Italian Cooperative Group, Istituto Nazionale Tumori, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Italian Cooperative Group, Istituto Nazionale Tumori, Milan","institution_ids":["https://openalex.org/I4210156707"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081002589","display_name":"Elena Negretti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"E. Negretti","raw_affiliation_strings":["Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","Istituto Nazionale Ricerca Cancer, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","institution_ids":["https://openalex.org/I4210156707"]},{"raw_affiliation_string":"Istituto Nazionale Ricerca Cancer, Milan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111577336","display_name":"Benvenuto Giannotti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"B. Giannotti","raw_affiliation_strings":["Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","Istituto Nazionale Ricerca Cancer, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","institution_ids":["https://openalex.org/I4210156707"]},{"raw_affiliation_string":"Istituto Nazionale Ricerca Cancer, Milan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043876294","display_name":"Laura Brogelli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"L. Brogelli","raw_affiliation_strings":["Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","Istituto Nazionale Ricerca Cancer, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","institution_ids":["https://openalex.org/I4210156707"]},{"raw_affiliation_string":"Istituto Nazionale Ricerca Cancer, Milan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081516681","display_name":"Isa Maura Brunetti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"I. Brunetti","raw_affiliation_strings":["Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","Istituto Nazionale Ricerca Cancer, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","institution_ids":["https://openalex.org/I4210156707"]},{"raw_affiliation_string":"Istituto Nazionale Ricerca Cancer, Milan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109094581","display_name":"M.R. Sertoli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. R. Sertoli","raw_affiliation_strings":["Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","Istituto Nazionale Ricerca Cancer, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","institution_ids":["https://openalex.org/I4210156707"]},{"raw_affiliation_string":"Istituto Nazionale Ricerca Cancer, Milan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107871286","display_name":"Maria Grazia Bernengo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. G. Bernengo","raw_affiliation_strings":["Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","Istituto Nazionale Ricerca Cancer, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","institution_ids":["https://openalex.org/I4210156707"]},{"raw_affiliation_string":"Istituto Nazionale Ricerca Cancer, Milan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013612580","display_name":"Maria Carla Sofra","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. C. Sofra","raw_affiliation_strings":["Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","Istituto Nazionale Ricerca Cancer, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","institution_ids":["https://openalex.org/I4210156707"]},{"raw_affiliation_string":"Istituto Nazionale Ricerca Cancer, Milan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016478199","display_name":"Giovanni Maifredi","orcid":"https://orcid.org/0000-0001-7008-6098","observed_orcids":["https://orcid.org/0000-0001-7008-6098"]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"G. Maifredi","raw_affiliation_strings":["Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","Istituto Nazionale Ricerca Cancer, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","institution_ids":["https://openalex.org/I4210156707"]},{"raw_affiliation_string":"Istituto Nazionale Ricerca Cancer, Milan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106792492","display_name":"G. Zumiani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"G. Zumiani","raw_affiliation_strings":["Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","Istituto Nazionale Ricerca Cancer, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","institution_ids":["https://openalex.org/I4210156707"]},{"raw_affiliation_string":"Istituto Nazionale Ricerca Cancer, Milan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070154306","display_name":"Giuseppe Cornelia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"G. Cornelia","raw_affiliation_strings":["Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","Istituto Nazionale Ricerca Cancer, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","institution_ids":["https://openalex.org/I4210156707"]},{"raw_affiliation_string":"Istituto Nazionale Ricerca Cancer, Milan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040934952","display_name":"Roberto Buzzoni","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"R. Buzzoni","raw_affiliation_strings":["Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","Fondazione IRCCS Istituto Nazionale dei Tumori"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","institution_ids":["https://openalex.org/I4210156707"]},{"raw_affiliation_string":"Fondazione IRCCS Istituto Nazionale dei Tumori","institution_ids":["https://openalex.org/I4210156707"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105140867","display_name":"Angelo Di Leo","orcid":"https://orcid.org/0000-0002-3665-9056","observed_orcids":["https://orcid.org/0000-0002-3665-9056"]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Di Leo","raw_affiliation_strings":["Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","Istituto Nazionale Ricerca Cancer, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","institution_ids":["https://openalex.org/I4210156707"]},{"raw_affiliation_string":"Istituto Nazionale Ricerca Cancer, Milan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065157044","display_name":"Domenico Criscuolo","orcid":"https://orcid.org/0009-0008-3265-5438","observed_orcids":["https://orcid.org/0009-0008-3265-5438"]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"D. Criscuolo","raw_affiliation_strings":["Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","Istituto Nazionale Ricerca Cancer, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","institution_ids":["https://openalex.org/I4210156707"]},{"raw_affiliation_string":"Istituto Nazionale Ricerca Cancer, Milan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108465953","display_name":"Giorgio Massimini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"G. Massimini","raw_affiliation_strings":["Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","Istituto Nazionale Ricerca Cancer, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","institution_ids":["https://openalex.org/I4210156707"]},{"raw_affiliation_string":"Istituto Nazionale Ricerca Cancer, Milan","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110523674","display_name":"N. Cascinelli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"N. Cascinelli","raw_affiliation_strings":["Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","Istituto Nazionale Ricerca Cancer, Milan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Response Modifier in Melanoma (B.RE.M.I.M.) Italian Cooperative Group. Istituto Nazionale Tumori. Milan, Italy","institution_ids":["https://openalex.org/I4210156707"]},{"raw_affiliation_string":"Istituto Nazionale Ricerca Cancer, Milan","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210156707"],"apc_list":null,"apc_paid":null,"fwci":2.3542,"has_fulltext":false,"cited_by_count":31,"citation_normalized_percentile":{"value":0.8917679,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"13","issue":"5","first_page":"405","last_page":"409"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/interferon-alfa-2a","display_name":"interferon alfa-2a","score":0.9409999847412109},{"id":"https://openalex.org/keywords/dacarbazine","display_name":"dacarbazine","score":0.996999979019165},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.8799999952316284},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.8500000238418579},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.7749999761581421},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.628000020980835},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.9100000262260437},{"id":"https://openalex.org/keywords/sepsis","display_name":"sepsis","score":0.7239999771118164},{"id":"https://openalex.org/keywords/duration-of-response","display_name":"duration of response","score":0.6679999828338623}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9603245258331299},{"id":"https://openalex.org/C2780964509","wikidata":"https://www.wikidata.org/wiki/Q416975","display_name":"Dacarbazine","level":3,"score":0.9165711402893066},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.7288450002670288},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.49218788743019104},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4481552541255951},{"id":"https://openalex.org/C2909179924","wikidata":"https://www.wikidata.org/wiki/Q6046488","display_name":"Alpha interferon","level":3,"score":0.4325754940509796},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.38081833720207214},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3560713529586792},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.3453085720539093},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.2787817120552063}],"mesh":[{"descriptor_ui":"D000077190","descriptor_name":"Interferon alpha-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003131","descriptor_name":"Combined Modality Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004341","descriptor_name":"Drug Evaluation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007558","descriptor_name":"Italy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012074","descriptor_name":"Remission Induction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1097/00000421-199010000-00008","doi":"https://doi.org/10.1097/00000421-199010000-00008","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00000421-199010000-00008","pdf_url":null,"source":{"id":"https://openalex.org/S130927242","display_name":"American Journal of Clinical Oncology","issn_l":"0277-3732","issn":["0277-3732","1537-453X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:2220660","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2220660","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American journal of clinical oncology","raw_type":"Clinical Trial"},{"id":"pmh:oai:iris.unito.it:2318/31566","doi":null,"is_oa":false,"landing_page_url":"http://hdl.handle.net/2318/31566","pdf_url":null,"source":{"id":"https://openalex.org/S4306400637","display_name":"Institutional Research Information System University of Turin (University of Turin)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I55143463","host_organization_name":"University of Turin","host_organization_lineage":["https://openalex.org/I55143463"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1991403320","https://openalex.org/W1791289689","https://openalex.org/W1516688668","https://openalex.org/W2437351620","https://openalex.org/W2245369264","https://openalex.org/W2027905327","https://openalex.org/W2003155823","https://openalex.org/W1989692594"],"abstract_inverted_index":{"Based":[0],"on":[1],"the":[2,29,46,61,69,80,112,143,173],"report":[3],"of":[4,7,37,48,63,103,115,161,175],"some":[5,169],"activity":[6,171],"combination":[8,159],"therapy":[9,110],"with":[10,89,164],"dacarbazine":[11],"(DTIC)":[12],"and":[13,31,54,73,92,111,131,148],"interferon":[14],"alpha-2a":[15,56,163],"(rIFN":[16],"alpha-2a)":[17],"in":[18,33,42,172],"disseminated":[19],"melanoma,":[20],"we":[21],"conducted":[22],"a":[23,34,76,100,158,165],"phase":[24],"II":[25],"study":[26],"to":[27,138],"determine":[28],"feasibility":[30],"efficacy":[32],"large":[35],"series":[36],"patients.":[38],"DTIC":[39],"was":[40,57,117,134],"administered":[41],"79":[43],"patients":[44,145],"at":[45,60],"dose":[47,62],"800":[49],"mg/m2":[50],"every":[51],"3":[52],"weeks":[53,72],"rIFN":[55,162],"given":[58],"daily":[59],"9":[64],"X":[65],"10(6)":[66],"IU":[67],"for":[68],"first":[70],"10":[71],"three":[74],"times":[75],"week":[77],"thereafter.":[78],"Among":[79],"75":[81],"evaluable":[82],"patients,":[83],"25%":[84],"achieved":[85],"an":[86],"objective":[87],"response,":[88],"8%":[90],"complete":[91],"17%":[93],"partial":[94],"remissions.":[95],"The":[96,122],"regression":[97],"occurred":[98],"within":[99],"mean":[101,113],"time":[102],"1.9":[104],"+/-":[105,119],"1.03":[106],"months":[107],"from":[108],"starting":[109],"duration":[114],"response":[116],"8.2":[118],"4.2":[120],"months.":[121],"major":[123],"side":[124],"effects":[125],"were":[126,151],"vomiting,":[127],"anorexia,":[128],"fever,":[129],"fatigue,":[130],"myalgia.":[132],"There":[133],"one":[135],"death":[136],"related":[137],"sepsis":[139],"after":[140],"myelosuppression.":[141],"In":[142],"other":[144],"bone":[146],"marrow":[147],"liver":[149],"toxicities":[150],"not":[152],"remarkable.":[153],"Our":[154],"data":[155],"reveal":[156],"that":[157],"regimen":[160],"cytotoxic":[166],"agent":[167],"has":[168],"therapeutic":[170],"management":[174],"advanced":[176],"malignant":[177],"melanoma.":[178]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2009929835","counts_by_year":[],"updated_date":"2026-11-18T13:11:19.462570","created_date":"2016-06-24T00:00:00"}
